Definium Therapeutics Past Earnings Performance
Past criteria checks 0/6
Definium Therapeutics's earnings have been declining at an average annual rate of -18.2%, while the Pharmaceuticals industry saw earnings growing at 8.6% annually.
Key information
-18.15%
Earnings growth rate
10.29%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | n/a |
| Return on equity | -128.72% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2025 |
Recent past performance updates
Recent updates
MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy
Oct 14Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges
Apr 21MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call
Jan 29Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
Nov 04Psychedelic Stocks: Focus On Their Cash
Aug 15MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
Jun 05Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Apr 04Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Feb 02Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans
May 23
We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely
Feb 07MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics
Oct 19MindMed announces proposed public offering of common shares
Sep 27MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances
Sep 20Revenue & Expenses Breakdown
How Definium Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 25 | 0 | -168 | 45 | 106 |
| 30 Jun 25 | 0 | -115 | 38 | 92 |
| 31 Mar 25 | 0 | -78 | 37 | 77 |
| 31 Dec 24 | 0 | -109 | 39 | 65 |
| 30 Sep 24 | 0 | -98 | 39 | 55 |
| 30 Jun 24 | 0 | -102 | 39 | 51 |
| 31 Mar 24 | 0 | -125 | 44 | 51 |
| 31 Dec 23 | 0 | -96 | 42 | 52 |
| 30 Sep 23 | 0 | -77 | 36 | 49 |
| 30 Jun 23 | 0 | -75 | 37 | 44 |
| 31 Mar 23 | 0 | -63 | 30 | 39 |
| 31 Dec 22 | 0 | -57 | 30 | 36 |
| 30 Sep 22 | 0 | -69 | 32 | 38 |
| 30 Jun 22 | 0 | -69 | 31 | 39 |
| 31 Mar 22 | 0 | -98 | 60 | 38 |
| 31 Dec 21 | 0 | -93 | 59 | 35 |
| 30 Sep 21 | 0 | -89 | 59 | 32 |
| 30 Jun 21 | 0 | -80 | 53 | 29 |
| 31 Mar 21 | 0 | -41 | 19 | 24 |
| 31 Dec 20 | 0 | -34 | 14 | 19 |
| 30 Sep 20 | 0 | -29 | 11 | 14 |
Quality Earnings: DFTX is currently unprofitable.
Growing Profit Margin: DFTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DFTX is unprofitable, and losses have increased over the past 5 years at a rate of 18.2% per year.
Accelerating Growth: Unable to compare DFTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DFTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.9%).
Return on Equity
High ROE: DFTX has a negative Return on Equity (-128.72%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/22 10:55 |
| End of Day Share Price | 2026/01/22 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Definium Therapeutics, Inc. is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Christopher Chen | Baird |
| null null | Baird |